Investigational Drug Information for Atrasentan
✉ Email this page to a colleague
What is the drug development status for Atrasentan?
Atrasentan is an investigational drug.
There have been 20 clinical trials for Atrasentan.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2001.
The most common disease conditions in clinical trials are Kidney Diseases, Prostatic Neoplasms, and Diabetic Nephropathies. The leading clinical trial sponsors are Abbott, National Cancer Institute (NCI), and AbbVie (prior sponsor, Abbott).
Summary for Atrasentan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,923 |
| WIPO Patent Applications | 1,223 |
| Japanese Patent Applications | 810 |
| Clinical Trial Progress | Phase 3 (2001-06-01) |
| Vendors | 43 |
Recent Clinical Trials for Atrasentan
| Title | Sponsor | Phase |
|---|---|---|
| Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy | Chinook Therapeutics, Inc. | Phase 2 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases | Chinook Therapeutics U.S., Inc. | Phase 2 |
| Atrasentan in Patients With IgA Nephropathy | Chinook Therapeutics U.S., Inc. | Phase 3 |
Clinical Trial Summary for Atrasentan
Top disease conditions for Atrasentan
Top clinical trial sponsors for Atrasentan
US Patents for Atrasentan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
